pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$LEGNLegend Biotech Corp

$LEGN18.57-3.88%
Somerset, NJ, USupdated 1d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
LB-1908
Adenocarcinoma Of The Gastroesophageal Junction

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 11, 2026
earnings
$LEGN18.57-3.88%
2mo ago
Legend Biotech Corp earnings
Legend Biotech Corp
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Legend Biotech Corp jobs →

News

  • The top 12 companies hiring in biopharma now
    Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
    biospace · 3d ago
  • Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
    Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…
    endpoints · 9d ago
  • J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
    Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
    biospace · 9d ago
  • 9 companies hiring in Pennsylvania now
    Looking for a biopharma job in Pennsylvania? Job postings in the state tripled year over year on BioSpace. These nine companies are hiring now.
    biospace · 11d ago
  • Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves
    → Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act. The company’s shares {$LEGN} are down 50% ...
    endpoints · 16d ago
  • Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
    After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
    fiercebiotech · 17d ago
  • Biopharma hiring hotspots: States, disciplines where demand is highest
    As biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other loca…
    biospace · 17d ago
  • Trending: Top biopharma disciplines with jobs live now
    From engineering to science/R&D, these top seven biopharma disciplines each have hundreds, and in one case over 1,000, positions posted on BioSpace.
    biospace · 17d ago
  • STAT+: Obesity drugmakers are testing in kids as young as 6
    Vera seeks kidney drug approval, early data from Syntis Bio, and other biotech news from The Readout
    stat · 19d ago
  • Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
    A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…
    fiercebiotech · 26d ago
view all news mentions →
identifiers
ticker
$LEGN
SEC CIK
0001801198
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?